Innate Biologics is at the forefront of developing innovative solutions for targeting, treating, and preventing inflammation through its proprietary platform of engineered bacterial effector proteins. This platform utilizes a unique approach by combining targeting sequences and protein transduction domains with effector domains in fusion proteins. This strategy allows for the precise delivery of anti-inflammatory proteins to specific organs and tissues, effectively addressing the innate intracellular inflammatory processes that can lead to various diseases when improperly activated. The company has re-engineered naturally occurring bacterial proteins to enhance their specificity and potency, creating targeted therapies that can modulate inflammatory responses at the molecular level.

The technology developed by Innate Biologics aims to revolutionize the treatment of inflammation-related conditions by focusing on intracellular signaling pathways. By leveraging proprietary protein engineering techniques, the company has created a platform that not only targets inflammation but also holds potential applications in both therapeutic and cosmeceutical markets. This innovative approach seeks to move beyond traditional non-targeted therapies, offering more effective solutions for conditions such as arthritis, asthma, acne, and autoimmune diseases. With a strong foundation in cutting-edge science and strategic collaborations, Innate Biologics is poised to make significant advancements in the field of inflammation management.

United States

Innate Biologics, LLC is a privately held company targeting, treating and preventing inflammation through the development of a first-of-its-kind recombinant protein platform, which specifically targets intracellular inflammatory signaling pathways. 

Innate Biologics

Company Details